Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Phys Chem B ; 127(20): 4396-4405, 2023 05 25.
Article in English | MEDLINE | ID: covidwho-2324522

ABSTRACT

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is considered as a key target for the design and development of COVID-19 drugs and inhibitors. Due to their unique structure and properties, ionic liquids (ILs) have many special interactions with proteins, showing great potential in biomedicine. Nevertheless, few research studies have been carried out on ILs and the spike RBD protein. Here, we explore the interaction of ILs and the RBD protein through large-scale molecular dynamics simulations (4 µs in total). It was found that IL cations with long alkyl chain lengths (nchain) could spontaneously bind to the cavity region of the RBD protein. The longer the alkyl chain is, the stabler the cations bind to the protein. The binding free energy (ΔG) had the same trend, peaking at nchain = 12 with -101.19 kJ/mol. The cationic chain lengths and their fit to the pocket are decisive factors that influence the binding strength of cations and proteins. The cationic imidazole ring has a high contact frequency with phenylalanine and tryptophan, and the hydrophobic residues phenylalanine, valine, leucine, and isoleucine are the most interacting residues with side chains of cations. Meanwhile, through analysis of the interaction energy, the hydrophobic and π-π interactions are the main contributors to the high affinity between cations and the RBD protein. In addition, the long-chain ILs would also act on the protein through clustering. These studies not only provide insights into the molecular interaction between ILs and the RBD of SARS-CoV-2 but also contribute to the rational design of IL-based drugs, drug carriers, and selective inhibitors as a therapeutic for SARS-CoV-2.


Subject(s)
COVID-19 , Ionic Liquids , Humans , SARS-CoV-2/metabolism , Spike Glycoprotein, Coronavirus/chemistry , Ionic Liquids/chemistry , Molecular Dynamics Simulation , Protein Binding , Cations , Phenylalanine/metabolism
2.
Int J Mol Sci ; 24(2)2023 Jan 14.
Article in English | MEDLINE | ID: covidwho-2233278

ABSTRACT

Witnessed by the ongoing spread of antimicrobial resistant bacteria as well as the recent global pandemic of the SARS-CoV-2 virus, the development of new disinfection strategies is of great importance, and novel substance classes as effective antimicrobials and virucides are urgently needed. Ionic liquids (ILs), low-melting salts, have been already recognized as efficient antimicrobial agents with prospects for antiviral potential. In this study, we examined the antiviral activity of 12 morpholinium based herbicidal ionic liquids with a tripartite test system, including enzyme inhibition tests, virucidal activity determination against five model viruses and activity against five bacterial species. The antimicrobial and enzymatic tests confirmed that the inhibiting activity of ILs corresponds with the number of long alkyl side chains and that [Dec2Mor]+ based ILs are promising candidates as novel antimicrobials. The virucidal tests showed that ILs antiviral activity depends on the type and structure of the virus, revealing enveloped Phi6 phage as highly susceptible to the ILs action, while the non-enveloped phages PRD1 and MS2 proved completely resistant to ionic liquids. Furthermore, a comparison of results obtained for P100 and P001 phages demonstrated for the first time that the susceptibility of viruses to ionic liquids can be dependent on differences in the phage tail structure.


Subject(s)
Anti-Infective Agents , Bacteriophages , COVID-19 , Ionic Liquids , Humans , Ionic Liquids/pharmacology , Ionic Liquids/chemistry , SARS-CoV-2 , Anti-Infective Agents/pharmacology , Anti-Infective Agents/chemistry , Antiviral Agents/pharmacology , Bacteria
3.
Environ Res ; 214(Pt 3): 113943, 2022 11.
Article in English | MEDLINE | ID: covidwho-1983018

ABSTRACT

The global pandemic situation due to COVID-19 has given rise to the massive use of disinfectant products, many of them based on silver atoms. After the use of these products, the silver passes into the aqueous effluents, becoming an emerging contaminant in waters. In this work, a novel procedure for the total and simultaneous removal of ionic and nanomeric silver in aqueous samples is introduced, employing magnetic nanoparticles wrapped with an ionic liquid (Fe3O4@IL) as a removal agent. Experimental variables such as pH, contact time, temperature, as well as pollutant and removal agent doses were studied to achieve the total elimination, exhibiting exceptional conditions for the removal of different concentrations of silvers species in water. The approach achieves 100% removal efficiency for the simultaneous removal of both silver species, goal not achieved previously. Also, 100% removal efficiency is reached for the both species separately, since ionic silver is adsorbed onto the Fe3O4, while nanomeric silver is extracted in the IL. Particularly, for concentrations within the range 50-200 µg L-1, total removal efficiency was reached for a wide range of temperatures and a pH range 7-9, achieved in just 15 min, for all cases. Additionally, the doses of Fe3O4@IL employed to remove all concentrations of silver were 13.7 mg. Characterization of Fe3O4@IL surfaces before and after the process was performed by means of Field Effect Scanning Electron Microscopy and Energy Dispersive X-ray Spectroscopy. Fe3O4@IL was recycled by employing 100 µL of 1% HNO3 solution, allowing its use for 10 additional silver removal cycles without loss of efficiency. The study of adsorption kinetics and equilibrium isotherms reveal a Freundlich-type adsorption, which suggests affinity between sites in the complex surface of Fe3O4@IL, and Elovich kinetics, indicative of chemisorption onto a heterogeneous surface, while the temperature shows no effect on the results.


Subject(s)
COVID-19 , Ionic Liquids , Magnetite Nanoparticles , Water Pollutants, Chemical , Adsorption , Humans , Hydrogen-Ion Concentration , Ionic Liquids/chemistry , Kinetics , Magnetite Nanoparticles/chemistry , Silver/chemistry , Water/chemistry , Water Pollutants, Chemical/analysis
4.
J Photochem Photobiol B ; 231: 112447, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1796437

ABSTRACT

Cuspareine as an antiviral alkaloid can be used in the treatment of COVID-19. In this study, we introduced the ionic liquids (ILs) concluded cuspareinium as a cation with CH3COO-, CF3COO-, and PF6 as anions. The optimized geometry, thermodynamic parameters, and reactivity descriptors were calculated with density functional theory (DFT) approach and time-dependent density functional theory (TD-DFT) using B3LYP/6-311G. In addition, the UV and IR spectra of the introduced ILs were investigated. Based on DFT calculation, the designed IL CH3COO- can be to the most suitable anions due to most solubility in the water. DFT studies displayed that all the introduced ILs have more polarity than pristine cuspareine and CH3COO--cuspareine is the most polarity due to high dipole moment. Also, the thermo- chemical data of the designed ionic liquids revealed that PF6-cuspareine is distinguished to be stable. A molecular docking study of the designed ILs with 6 LU7 protease was performed to display interactions and binding energy. Results of molecular docking displayed that CH3COO- ion liquid has the highest binding energy (- 7.20 kcal/mol) and Ala7, and Lys 5 residues are involved in an interaction. DFT and molecular docking studies of cuspareine as alkaloid based on ionic liquids can be helpful to for more pharmaceutical and biological researches of cuspareine as an antiviral agent against COVID-19.


Subject(s)
Alkaloids , COVID-19 Drug Treatment , Ionic Liquids , Alkaloids/pharmacology , Anions/chemistry , Antiviral Agents/pharmacology , Humans , Ionic Liquids/chemistry , Molecular Docking Simulation , Quinolines
5.
Molecules ; 26(16)2021 Aug 07.
Article in English | MEDLINE | ID: covidwho-1399345

ABSTRACT

Ionic liquids have unique chemical properties that have fascinated scientists in many fields. The effects of adding ionic liquids to biocatalysts are many and varied. The uses of ionic liquids in biocatalysis include improved separations and phase behaviour, reduction in toxicity, and stabilization of protein structures. As the ionic liquid state of the art has progressed, concepts of what can be achieved in biocatalysis using ionic liquids have evolved and more beneficial effects have been discovered. In this review ionic liquids for whole-cell and isolated enzyme biocatalysis will be discussed with an emphasis on the latest developments, and a look to the future.


Subject(s)
Biocatalysis , Cells/metabolism , Enzymes/isolation & purification , Ionic Liquids/chemistry , Solubility
6.
Mol Pharm ; 18(8): 3108-3115, 2021 08 02.
Article in English | MEDLINE | ID: covidwho-1305357

ABSTRACT

Coronavirus disease 2019 (COVID-19) has spread across the world, and no specific antiviral drugs have yet been approved to combat this disease. Favipiravir (FAV) is an antiviral drug that is currently in clinical trials for use against COVID-19. However, the delivery of FAV is challenging because of its limited solubility, and its formulation is difficult with common organic solvents and water. To address these issues, four FAV ionic liquids (FAV-ILs) were synthesized as potent antiviral prodrugs and were fully characterized by nuclear magnetic resonance (NMR) spectroscopy, Fourier-transform infrared (FT-IR) spectrometry, powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), derivative thermogravimetry (DTG), and differential scanning calorimetry (DSC). The aqueous solubility and in vivo pharmacokinetic properties of the FAV-ILs were also evaluated. The FAV-ILs exhibited improved aqueous solubility by 78 to 125 orders of magnitude when compared with that of free FAV. Upon oral dosing in mice, the absolute bioavailability of the ß-alanine ethyl ester FAV formulation was increased 1.9-fold compared with that of the control FAV formulation. The peak blood concentration, elimination half-life, and mean absorption time of FAV were also increased by 1.5-, 2.0-, and 1.5-fold, respectively, compared with the control. Furthermore, the FAV in the FAV-ILs exhibited significantly different biodistribution compared with the control FAV formulation. Interestingly, drug accumulation in the lungs and liver was improved 1.5-fold and 1.3-fold, respectively, compared with the control FAV formulation. These results indicate that the use of ILs exhibits potential as a simple, scalable strategy to improve the solubility and oral absorption of hydrophobic drugs, such as FAV.


Subject(s)
Amides/administration & dosage , Antiviral Agents/administration & dosage , Ionic Liquids/chemistry , Pyrazines/administration & dosage , Administration, Oral , Amides/chemical synthesis , Amides/chemistry , Amides/pharmacokinetics , Animals , Female , Mice , Mice, Inbred BALB C , Pyrazines/chemical synthesis , Pyrazines/chemistry , Pyrazines/pharmacokinetics , Solubility , Tissue Distribution , COVID-19 Drug Treatment
7.
Int J Mol Sci ; 22(13)2021 Jun 24.
Article in English | MEDLINE | ID: covidwho-1304661

ABSTRACT

Quaternary ammonium compounds (QACs) belong to a well-known class of cationic biocides with a broad spectrum of antimicrobial activity. They are used as essential components in surfactants, personal hygiene products, cosmetics, softeners, dyes, biological dyes, antiseptics, and disinfectants. Simple but varied in their structure, QACs are divided into several subclasses: Mono-, bis-, multi-, and poly-derivatives. Since the beginning of the 20th century, a significant amount of work has been dedicated to the advancement of this class of biocides. Thus, more than 700 articles on QACs were published only in 2020, according to the modern literature. The structural variability and diverse biological activity of ionic liquids (ILs) make them highly prospective for developing new types of biocides. QACs and ILs bear a common key element in the molecular structure-quaternary positively charged nitrogen atoms within a cyclic or acyclic structural framework. The state-of-the-art research level and paramount demand in modern society recall the rapid development of a new generation of tunable antimicrobials. This review focuses on the main QACs exhibiting antimicrobial and antifungal properties, commercial products based on QACs, and the latest discoveries in QACs and ILs connected with biocide development.


Subject(s)
Disinfectants/chemistry , Disinfectants/pharmacology , Ionic Liquids/chemistry , Quaternary Ammonium Compounds/chemistry , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity Relationship
8.
Int J Mol Sci ; 21(17)2020 Aug 20.
Article in English | MEDLINE | ID: covidwho-725538

ABSTRACT

At the moment, there are no U.S. Food and Drug Administration (U.S. FDA)-approved drugs for the treatment of COVID-19, although several antiviral drugs are available for repurposing. Many of these drugs suffer from polymorphic transformations with changes in the drug's safety and efficacy; many are poorly soluble, poorly bioavailable drugs. Current tools to reformulate antiviral APIs into safer and more bioavailable forms include pharmaceutical salts and cocrystals, even though it is difficult to classify solid forms into these regulatory-wise mutually exclusive categories. Pure liquid salt forms of APIs, ionic liquids that incorporate APIs into their structures (API-ILs) present all the advantages that salt forms provide from a pharmaceutical standpoint, without being subject to solid-state matter problems. In this perspective article, the myths and the most voiced concerns holding back implementation of API-ILs are examined, and two case studies of API-ILs antivirals (the amphoteric acyclovir and GSK2838232) are presented in detail, with a focus on drug property improvement. We advocate that the industry should consider the advantages of API-ILs which could be the genesis of disruptive innovation and believe that in order for the industry to grow and develop, the industry should be comfortable with a certain element of risk because progress often only comes from trying something different.


Subject(s)
Acyclovir/chemistry , Antiviral Agents/chemistry , Betacoronavirus/drug effects , Butyrates/chemistry , Chrysenes/chemistry , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Acyclovir/pharmacology , Antiviral Agents/pharmacology , Biological Availability , Butyrates/pharmacology , COVID-19 , Chemistry, Pharmaceutical/methods , Chrysenes/pharmacology , Drug Repositioning/methods , Humans , Ionic Liquids/chemistry , Pandemics , Pentacyclic Triterpenes , SARS-CoV-2 , Solubility , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL